Market Signal Briefing

New York, New York--(Newsfile Corp. - March 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased PomDoctor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the PomDoctor class action, go to https://rosenlegal.com/submit-form/?case_id=52621 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) PomDoctor was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) PomDoctor's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants' positive statements about PomDoctor's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To join the PomDoctor class action, go to https://rosenlegal.com/submit-form/?case_id=52621 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286640

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 23, 2026 to file lead plaintiff applications in a securities class action lawsuit against BellRing Brands, Inc. (NYSE: BRBR), if they purchased or otherwise acquired the Company's securities between November 19, 2024 and August 4, 2025, inclusive (the "Class Period").  This action is pending in the United States District Court for the Southern District of New York.

Get Help

BellRing investors should visit us at https://claimsfiler.com/cases/nyse-brbr/ or call toll-free (844) 367-9658.  Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

BellRing and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On May 6, 2025, the Company disclosed that "several key retailers lowered their weeks of supply on hand, which is expected to be a mid-single-digit headwind to our third quarter growth," and that "[w]e now expect Q3 sales growth of low single digits." On this news, the price of BellRing's shares fell $14.88 per share, or 19%, from $78.43 per share on May 5, 2025, to close at $63.55 per share on May 6, 2025, on unusually heavy trading volume.

Then, on August 4, 2025, post-market, the Company reported its fiscal 3Q 2025 financial results, disclosing a disappointing new 2025 sales outlook, stating "BellRing management has narrowed its fiscal year 2025 outlook for net sales to [a] range between $2.28-$2.32 billion," due to "several other competitors" gaining space to sell their products with a large retailer and that "it is not surprising to see new protein RTDs enter[ed]" the convenient nutrition market.  On this news, the price of BellRing's shares fell $17.46 per share, or nearly 33%, from $53.64 per share on August 4, 2025, to $36.18 per share on August 5, 2025, on unusually heavy trading volume.

The case is Denha v. BellRing Brands, Inc., No. 26-cv-00575.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

SOURCE ClaimsFiler

, /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) ("uniQure" or the "Company"), if they purchased or otherwise acquired the Company's shares between September 24, 2025 and October 31, 2025, inclusive (the "Class Period").  This action is pending in the United States District Court for the Southern District of New York.

Get Help

uniQure investors should visit us at https://claimsfiler.com/cases/nasdaq-qure/ or call toll-free (844) 367-9658.  Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

uniQure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

During the Class Period, the Company represented to investors that there was a high likelihood that its leading drug candidate, AMT-130, would receive accelerated approval from the U.S. Food and Drug Administration ("FDA") after the Company's planned Biologics License Application ("BLA") submission in the first quarter of 2026. However, on November 3, 2025, the Company disclosed that "the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission" and as a result, "the timing of the BLA submission for AMT-130 is now unclear."

On this news, the price of uniQure's shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025.

The case is Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

SOURCE ClaimsFiler

, /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) ("Corcept" or the "Company"), if they purchased or otherwise acquired the Company's shares between October 31, 2024 and December 30, 2025, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of California.

Get Help

Corcept investors should visit us at https://claimsfiler.com/cases/nasdaq-cort-1/ or call toll-free (844) 367-9658.  Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration ("FDA") after the Company's New Drug Application ("NDA") submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter ("CRL") regarding the NDA for relacorilant and that it had "concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness."

On this news, the price of Corcept's shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.

The case is Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

SOURCE ClaimsFiler

, /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 1, 2026 to file lead plaintiff applications in a securities class action lawsuit against Apollo Global Management, Inc. (NYSE: APO) ("Apollo" or the "Company"), if they purchased or otherwise acquired the Company's securities between May 10, 2021 and February 21, 2026, inclusive (the "Class Period").  This action is pending in the United States District Court for the Southern District of New York.

Get Help

Apollo investors should visit us at https://claimsfiler.com/cases/nyse-apo/ or call toll-free (844) 367-9658.  Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Apollo and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company's leadership figures, including defendants Marc Rowan and Leon Black, frequently communicated with Jeffrey Epstein in the 2010s regarding the Company's business; (ii) as a result, the Company's assertion that Apollo Global had never done business with Jeffrey Epstein was untrue; (iii) because of the entanglement between Apollo Global's leaders and Jeffrey Epstein, the harm to the Company's reputation was more than a mere possibility; and (iv) as a result, the Company's statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

The case is Feldman v. Apollo Global Management, Inc., et al., Case No. 26-cv-01692.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

SOURCE ClaimsFiler

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis.

In a week marked by broader market volatility, cybersecurity firms CrowdStrike and Okta emerged as outperformers after exceeding their Q4 expectations.

SBA Communications Corporation (SBAC) Morgan Stanley Technology, Media & Telecom Conference 2026 March 3, 2026 2:30 PM EST

Company Participants

Marc Montagner - Executive VP & CFO

Conference Call Participants

Cameron McVeigh - Morgan Stanley, Research Division

Presentation

Cameron McVeigh
Morgan Stanley, Research Division

Okay. So let's get started. Cameron McVeigh, the communications infrastructure analyst here at Morgan Stanley; Ben Swinburne, the communications infrastructure, media, telecom, cable analyst; and Marc Montagner, the CFO of SBA Communications. Welcome, Marc.

Marc Montagner
Executive VP & CFO

Thank you.

Question-and-Answer Session

Cameron McVeigh
Morgan Stanley, Research Division

Before we get started, let me read this. For important disclosures, please see the Morgan Stanley Research Disclosure website. If you have any questions, please reach out to your Morgan Stanley sales representative.

With that, we will get started. Marc, just to start, I want to get your thoughts on the growth outlook for the broader tower industry and what you consider the main growth drivers for the industry today.

Marc Montagner
Executive VP & CFO

I think if you really look at our business, specifically in the U.S., you have a co-location for densification or extra coverage and amendment for the existing equipment. So that's really driving the growth in terms of revenue growth. Let's just step back a little bit, right? The catalyst in this industry, I've been in this industry for 30 years, key areas, buy spectrum, and they roll out next-generation technology. They get about a 10x increase on the capacity versus the prior generation and an exponential cut in terms of the cost per bit, in terms of delivering a cost over the airway. If you just cram more bits per hertz. That's really been the driver for the industry for the past 30 years.

I mean, 30 years ago, EBITDA margins for

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Trip.com Group Limited (NASDAQ: TCOM) resulting from allegations that Trip.com Group Limited may have issued materially misleading business information to the investing public.

So What: If you purchased Trip.com Group Limited securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=50668 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On January 14, 2026, Investing.com published an article entitled "Trip.com stock falls after Chinese regulators launch antitrust probe." The article stated that Trip.com stock fell after "the Chinese travel service provider disclosed it is under investigation by China's market regulator for potential antitrust violations."

On this news, Trip.com American Depositary Shares ("ADS") fell 17% on January 14, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Vancouver, British Columbia – March 6, 2026 – TheNewswire  – Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (the “Company”) is pleased to announce a non-brokered private placement (the “Offering”) of up to 13,333,333 units of the Company (the “Units”) at a price of $0.15 per Unit for gross proceeds of up to $2,000,000.

Each Unit will consist of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will entitle the holder to acquire one additional Common Share at a price of $0.25 per share for a period of 24 months from the date of issuance.

The Company may accelerate the expiry date of the Warrants, at its discretion, if the closing price of the Company’s common shares on the Canadian Securities Exchange (the “CSE”) is equal to or greater than $0.75 for a period of five (5) consecutive trading days. In such event, the Company may provide notice to the holders of the Warrants that the expiry date of the Warrants will be accelerated to a date that is 30 days from the date of such notice. Any Warrants not exercised prior to the accelerated expiry date will automatically expire.

The net proceeds from the financing will be used to advance exploration activities on the Company’s mineral projects currently under option, including geological work, target development and related exploration programs. A portion of the proceeds may also be allocated to general and administrative expenses and working capital.

The Offering may close in one or more tranches and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including approval of the CSE. The Company may pay finder’s fees and/or issue finder’s warrants in connection with the Offering in accordance with applicable securities laws and CSE policies.

All securities issued pursuant to the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. 

United States Securities Law Disclosure

The securities issued under the Offering have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

  ON BEHALF OF THE BOARD OF DIRECTORS

George Yordanov

George Yordanov
President and CEO

Telephone: 604-687-2038

  About Canadian GoldCamps Corp.

  Canadian GoldCamps Corp. is a project generator, explorer and developer focused on gold opportunities in Canada. The Company’s strategy is to acquire and advance high-quality assets and progress them through disciplined, technically driven exploration

  The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

  Forward-Looking Statements

  This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plans”, “expects”, “intends”, “anticipates”, “believes”, “estimates”, “may”, “will”, “potential”, “proposed”, and similar expressions, or statements that certain events or conditions “may”, “could”, “would”, or “might” occur.

  Forward-looking statements in this news release include, but are not limited to, statements regarding: the completion of the Offering; the anticipated gross proceeds of the Offering; the timing and ability of the Company to close the Offering, including the closing of one or more tranches; the intended use of proceeds from the Offering; the potential payment of finder’s fees or issuance of finder’s warrants; and the receipt of all necessary approvals, including approval of the Canadian Securities Exchange.

  Forward-looking statements are based on management’s current expectations and assumptions, including, without limitation, that the Company will be able to successfully complete the Offering on the terms described herein, obtain all necessary regulatory approvals, and utilize the proceeds of the Offering as currently anticipated.

  Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such risks and uncertainties include, but are not limited to: the risk that the Offering may not be completed as currently contemplated or at all; the risk that regulatory approvals, including approval of the Canadian Securities Exchange, may not be obtained in a timely manner or at all; market conditions and investor demand for securities of the Company; and general economic, market, and financing conditions.

  Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct, and actual results and future events could differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are made as of the date of this news release, and the Company undertakes no obligation to update or revise them, except as required by applicable law.

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - Eureka Lithium Corp. (CSE: ERKA) (OTCQB: UREKF) (FSE: S58) ("Eureka Lithium" or "Eureka" or the "Company") announces that it has allowed to lapse approximately 1094 mineral claims comprising the Raglan West project, approximately 550 mineral claims comprising the Raglan South project and approximately 1601 mineral claims comprising the New Leaf project (collectively making up the "Nunavik Projects"). Accordingly, at this time, the Company retains approximately 158 claims ("Remaining Claims") relating to the Nunavik projects.

It seemed as if someone had switched off the power supplying Algonquin Power & Utilities (AQN 10.68%) stock on the last trading day of the week. Investors aggressively sold out of the veteran utility's equity that day, as they were clearly disappointed by the company's 2027 guidance miss in its latest earnings report. The stock closed that trading session down more than 12%.

Twin increases Well before market open on Friday, Algonquin took the wraps off its fourth-quarter and full-year 2025 results. For the three-month stretch, the utility's revenue was $630.7 million, representing year-over-year growth of almost 8%. Net income not under generally accepted accounting principles (GAAP) rose more steeply, increasing by 11% to $47.2 million ($0.06 per share).

Image source: Getty Images.

That meant a pair of beats for Algonquin, since analysts tracking the stock were averaging estimates of $616.6 million for revenue, and $0.05 per share for non-GAAP (adjusted) net income.

Algonquin has slimmed down, from a sprawling business straddling both traditional and next-generation renewable utility services to a more pure-play business focusing on the former.

It cited this "back to basics" strategy as a factor in its growth during the quarter. The company quoted CEO Rod West as saying that "During the year, we made substantial regulatory progress across our electric, gas and water utilities, began realizing the benefits of a more disciplined operating model."

Today's Change

(

-10.68

%) $

-0.73

Current Price

$

6.14

Power shortage West and his team reaffirmed the company's full-year 2026 profitability guidance, maintaining its adjusted net income forecast of $0.35 to $0.37 per share. They also set a forecast for the following year of $0.38 to $0.42 per share. The per-share consensus analyst estimates for the two years are $0.36 and $0.45, respectively.

That means a projected bottom-line miss on 2027, which didn't make Mr. Market all that happy. Personally, I don't think the company deserved such a robust sell-off on the results, as it's still an important operator and it seems to be going in the right direction with the corporate diet it's on. I'd consider this a potential bargain on the price decline.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Investing $1,000 usually isn't a stressful endeavor simply because (for most households anyway) it's not a life-changing amount of money; a luxury handbag or a nice weekend getaway can easily cost just as much.

Figuring out how to put $50,000 to work generating passive income, however, is a different story. This is a much more serious amount of money for most people, and must be handled in a way that makes the most effective use of it while minimizing risk.

To this end, here's a rundown of five dividend stocks to consider if you're looking to invest a bigger sum of money to produce reliable recurring income. In the same order you'll likely want to add them to your portfolio...

1. Verizon If you're looking for some capital appreciation even from your dividend-paying holdings, Verizon Communications (VZ 0.12%) offers some, but not nearly enough to view it as even a modest growth holding. It's first and foremost (and almost entirely) an income stock. But it plays this role extremely well, offering newcomers a chance to plug into a forward-looking yield of 5.6%, which is based on a dividend that's now been raised for 19 consecutive years.

The reason these payments are apt to endure indefinitely isn't tough to figure out. Most people living in the U.S. market it serves are practically addicted to their mobile phones, and have no intention of giving them up. Harmony Healthcare IT reports the average American spends more than five hours every day looking at their phone screen, for perspective.

Today's Change

(

-0.12

%) $

-0.06

Current Price

$

51.12

2. Realty Income Technically speaking, it's not a stock ... at least not in the sense that most investors understand publicly traded shares of conventional corporations. Although it's bought and sold via an exchange like any other ticker, Realty Income (O +0.26%) is a real estate investment trust, or REIT, for short. That just means it owns a bunch of revenue-generating real estate. As long as the majority of its profits are passed along to shareholders in the form of dividends, it's not first taxed at the corporate level. That ultimately means its investors put more money in their pockets.

That's not the chief reason that income-seeking investors might want to own this or any other REIT though. For that matter, neither is its respectable forward-looking yield of 4.9%. Rather, the most compelling aspect of owning a stake in Realty Income is that it makes its dividend payments every month rather than every quarter, at the same cadence people incur bills. The fact that it's also raised its annualized per-share payout every year for the past 31 years, of course, only bolsters the bullish argument.

3. ADP With just a passing look, Automatic Data Processing (ADP +1.59%) -- you'll likely know the payroll processor by its more familiar name, "ADP" -- doesn't look like a heroic income-generating stock. Its dividend yield of 3.2% is OK, but hardly thrilling.

Image source: Getty Images.

Now take a step back and look at the bigger picture. Over the course of the past 10 years this reliably profitable company's quarterly per-share dividend payment has more than doubled, from $0.53 in early 2016 to $1.70 per share now, extending a long-established pace of dividend growth. It's just the nature of its business model paired with the additions of related offerings like personnel time and attendance solutions, benefits management, employee recruitment, and other HR functions.

4. Brookfield Asset Management Just as the name suggests, Brookfield Asset Management (BAM 2.46%) is an investment management outfit. It oversees a handful of publicly traded partnerships that bear the same Brookfield name, in fact, scraping off a small fee from these entities' total values every calendar quarter.

The company is compellingly different than most other mutual fund and exchange-traded fund (ETF) managers though. Rather than establishing investment pools that will buy anything and everything, Brookfield is hyper-focused on proven growth industries like renewable energy, artificial intelligence (AI) data centers, water infrastructure, logistics, power distribution, and more. Moreover, most of its holdings are privately owned organizations rather than publicly traded entities, giving investors a chance to own stakes in attractive businesses that aren't investable in a conventional brokerage account.

Today's Change

(

-2.46

%) $

-1.16

Current Price

$

46.10

Perhaps more important, while this ticker's forward-looking yield of 4.3% is solid to be sure, the company's long-term annualized growth target of between 15% and 20% per year is completely achievable, given the nature of its underlying businesses. Indeed, this year's per-share payment is 15% better than last year's, which was 15% better than 2023's.

5. JPMorgan Equity Premium Income ETF Lastly, if you already own the four dividend stocks above (or enough names like them with similar yields and risk profiles), consider adding the JPMorgan Equity Premium Income ETF (JEPI 0.84%) to your portfolio while its trailing 30-day dividend yield stands at just under 7%.

That big number comes with an equally big footnote. That is, this yield isn't consistent. Sometimes it's less. Other times it's more. Over the course of the past 12 months its dividend yield has averaged over 8%, but at times it can be measurably less than its current 7%.

Given the sheer size of its monthly (yes, monthly) payouts most of the time though, this uncertainty may be worth it to investors who are also already collecting more predictable passive income from other holdings.

The JPMorgan Equity Premium Income ETF is able to generate this sort of income by "writing" covered call options. That just means it sells call options on stocks it also owns, essentially using these stock positions as collateral for these option trades that might eventually need to be undone one way or another. Whether or not it gets to keep these shares or is forced to sell them doesn't change the fact, however, that writing -- or selling -- covered call options repeatedly generates real cash flow.

The only arguable catch here is that JEPI's price tends to underperform its benchmark S&P 500 essentially because it's converting what could have been long-term capital gains into short-term income. In other words, you'll achieve about the same overall net return with this JPMorgan ETF that you would with an S&P 500 index fund. You'll just be achieving most of it in the form of dividend income rather than through price appreciation.

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”), have until May 5, 2026 to seek appointment as lead plaintiff of the Soleno class action lawsuit. Captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979 (N.D. Cal.), the Soleno class action lawsuit charges Soleno and certain of Soleno’s top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Soleno class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-soleno-therapeutics-inc-class-action-lawsuit-slno.html

You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: Soleno is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases. At the time of the Soleno class action lawsuit’s filing, Soleno’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome (“PWS”).

The Soleno class action lawsuit alleges defendants throughout the Class Period failed to disclose that: (i) the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (ii) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by Soleno or its executives; and (iii) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

On August 15, 2025, the Soleno investor class action alleges that Scorpion Capital LLC published a critical report regarding Soleno, DCCR, and Soleno’s Phase 3 clinical trial program, titled “Russian Roulette With Prader-Willi Children: How The Latest Rare Disease Price-Gouging Scheme Fleeced the FDA, Parents, And Its Own Study Investigators With A Worthless, Toxic Drug; Suspect Data; And Sham Clinical Trials To Push A $500K/Year Knockoff Of A 50-Year-Old Generic Compound – Triggering One Of The Worst Launch Failures And Safety Catastrophes In Post-Approval History.” On this news, the price of Soleno common stock declined nearly 12% over two trading days, the complaint alleges.

Then, on September 10, 2025, Soleno filed with the U.S. Securities and Exchange Commission a current event report on Form 8-K disclosing that a patient had died after taking DCCR, the Soleno shareholder lawsuit alleges. On this news, the price of Soleno common stock declined approximately 19% over two trading days, the complaint alleges.

Finally, on November 4, 2025, Soleno reported its financial results for its third fiscal quarter ended September 30, 2025, revealing that the Scorpion Capital Report had caused a “disruption” in DCCR’s launch trajectory and concerns within the PWS community, with a lower number of patient start forms and increased discontinuations beginning after the report’s publication, the Soleno class action alleges. On this news, the price of Soleno common stock declined approximately 27%, the complaint alleges

The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Soleno common stock during the Class Period to seek appointment as lead plaintiff in the Soleno class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Soleno investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Soleno shareholder class action lawsuit. An investor’s ability to share in any potential future recovery of the Soleno class action lawsuit is not dependent upon serving as lead plaintiff.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]

New York, New York--(Newsfile Corp. - March 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers Class A common stock of Snowflake Inc. (NYSE: SNOW) between June 27, 2023 and the close of the market on February 28, 2024 (4:00 p.m. ET), inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 27, 2026.

SO WHAT: If you purchased Snowflake Class A common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Snowflake class action, go to https://rosenlegal.com/submit-form/?case_id=22950 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants repeatedly made positive statements about the state of its business, including positive statements about customer usage of, and new developments for, its products. At the same time, defendants failed to disclose that: (1) product efficiency gains, Iceberg Tables and tiered storage pricing were expected to have a material negative impact on consumption and revenues, and (2) as a result, defendants' positive statements about consumption patterns, revenues, and demand for Snowflake products lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Snowflake class action, go to https://rosenlegal.com/submit-form/?case_id=22950 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286618

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Bitfarms (BITF 8.33%) is a Canadian company making a potentially lucrative transition from Bitcoin mining to AI data centers. Last month, its board approved plans to move the company to the U.S. and rebrand as Keel Infrastructure.

It doesn't cost much to add Bitfarms to your portfolio, as the current price is a little over $2 a share. Is this an opportunity to get in early on a stock set to deliver life-changing returns?

Image source: Getty Images.

The AI infrastructure pivot is a popular move for Bitcoin mining companies, and it makes sense from a financial perspective. They go from mining a highly volatile cryptocurrency, with rewards that are cut in half about every four years, to providing data center capacity for top AI companies.

For an idea of how much that can generate, Cipher Mining, another miner pivoting to AI infrastructure, signed a 15-year lease with Amazon Web Services last month. The deal is worth approximately $5.5 billion, about $367 million per year, for 300 megawatts of data center capacity.

Bitfarms has an impressive 2.1 gigawatts in its North American energy portfolio. Last November, it signed a binding agreement with an unnamed American multinational for $128 million to provide 18 megawatts of data center capacity. If Bitfarms can continue lining up deals like these, its revenue (and share price) could skyrocket.

Today's Change

(

-8.33

%) $

-0.18

Current Price

$

2.04

However, there's plenty of competition for those AI hosting contracts, both from other mining operations and established data center providers, including Applied Digital and Equinix. The transition to AI infrastructure is also an expensive one, and Bitfarms is already operating at a loss, with $96 million in trailing net losses.

Given the intense competition in this space, I'm doubtful Bitfarms is a millionaire-maker. It could still deliver excellent returns, but it's a high-risk, high-reward stock, so be cautious about how much you invest.

Lyle Daly has positions in Bitcoin. The Motley Fool has positions in and recommends Amazon, Bitcoin, and Equinix. The Motley Fool has a disclosure policy.

Key Takeaways The 2025 Q4 earnings season is nearing its end, with the period overall reflecting positivity. The 2026 Q1 cycle will pick up notable steam with the release of the big banks results next month. Oracle and Adobe, who have struggled notably recently, reflect two big releases coming next week. We consider Oracle’s (ORCL - Free Report) quarterly release on Tuesday (March 10th) and Adobe's (ADBE - Free Report) on Thursday (March 12th) among the early reports of the 2026 Q1 earnings season. Both of these companies will be releasing results for their respective fiscal quarters ending in February, which we count as part of the March-quarter tally.

The 2026 Q1 earnings season will take the spotlight when the big banks report their results in about four weeks. But we will already have seen fiscal February-quarter results from almost two dozen companies by then, including Oracle and Adobe.

In fact, Oracle and Adobe aren’t the first such Q1 reporters already; that distinction goes to AutoZone and Costco, whose quarterly releases for their fiscal quarters ending in February kicked off the 2026 Q1 earnings season.

Before headlines that have led to spiking oil prices as a result of the latest Middle East conflict started dominating market discourse, the issues facing the market were mostly tied to developments in the artificial intelligence space. Specifically, there has been persistent disquiet about the ever-rising levels of spend by mega-cap Tech players on setting up AI infrastructure, and worries about the threats AI poses to the long-term profitability of software businesses.

Oracle and Adobe shares have struggled lately, with Oracle facing headwinds related to its AI-centric spending plans. At the same time, Adobe's downbeat sentiment is tied to the long-term impact of AI on its core business. You can see this in the one-year performance of Oracle and Adobe shares relative to the S&P 500 index (red line, up +21.2%) and the Zacks Tech sector (green line, up +30%).

Image Source: Zacks Investment Research

Oracle is spending heavily on data centers it considers essential to its AI goals, but it lacks the financial firepower of other hyperscalers such as Microsoft, Alphabet, and Amazon. The company’s AI fortunes are also seen as closely tied to OpenAI, which has contracted to use a large portion of Oracle’s future datacenter capacity.

Unlike the Mag 7 hyperscalers, Oracle’s capex needs far exceed its internal cash flows, and the company will need outside funding at least through the next three years. The complicating factor for Oracle management is that their investment-grade credit profile will likely be at risk if they choose to fund all of their capital needs through the debt markets. Shareholders, on the other hand, don’t want to lose sleep over Oracle management diluting their ownership through secondary equity offerings.

Oracle shares were down big following the last quarterly release on December 10th, when the above funding issue took center stage, but overall quarterly results were mixed as well. The expectation is that Oracle will report $1.70 per share in earnings on $16.89 billion in revenues, representing year-over-year changes of +15.7% and +19.5%, respectively. The revisions trend has been stable, with estimates essentially unchanged over the last two months.

For Adobe, the expectation is of $5.88 per share in earnings on $6.28 billion in revenues, representing year-over-year changes of +15.8% and +9.9%, respectively. Estimates for the February quarter have been stable over the past two months, but the same for the current fiscal year (FY ends in November) have been modestly under pressure.

The Earnings Big Picture

For 2026 Q1 as a whole, total S&P 500 earnings are expected to increase by +11.4% from the same period last year on +8.5% higher revenues.

The chart below shows the Q1 earnings and revenue growth expectations in the context of where growth has been in the preceding five quarters and what is expected in the coming three quarters.

Image Source: Zacks Investment Research

Estimates for the current period (2026 Q1) have largely been stable, with a modest, though steady uptick in recent weeks, as the chart below shows.

Image Source: Zacks Investment Research

The chart below shows the overall earnings picture on a calendar-year basis, with double-digit earnings growth expected in 2025 and 2026.

Image Source: Zacks Investment Research

A quick comment on ongoing market volatility in response to developments in the Middle East. Please keep in mind that for these almost upbeat earnings expectations to come true, we need energy prices to return to where they were a few days ago, as an extended period of spiking oil prices has material negative implications for households as well as businesses.

2025 Q4 Earnings Season Scorecard

We are in that part of the reporting cycle when the preceding earnings season (2025 Q4 in this case) has not yet fully ended, even as the coming earnings season (2026 Q1) has begun, as we noted earlier.

Through Friday, March 6th, we have seen Q4 results from 493 S&P 500 members, or 98.6% of the index’s total membership. Total earnings for these companies are up +14.1% from the same period last year on +9.1% higher revenues, with 75.3% beating EPS estimates and 72.6% beating revenue estimates.

We have more than 250 companies on deck to report results this week, most of which qualify as belonging to the 2025 Q4 bucket, but some will belong to the 2026 Q1 tally, as will be the case for Oracle and Adobe.

The comparison charts below show the growth rates for companies that have reported, along with what we have seen from this same group of companies in other recent periods.

Image Source: Zacks Investment Research

The comparison charts below put the Q4 EPS and revenue beats percentages for this group of companies relative to what we had seen from them in other recent periods.

Image Source: Zacks Investment Research

For a detailed look at the overall earnings picture, including expectations for the coming periods, please check out our weekly Earnings Trends report >>>> Looking Ahead to the Q1 Earnings Season 

Raia Drogasil S.A. (RADLY) Q4 2025 Earnings Call March 4, 2026 8:00 AM EST

Company Participants

Renato Raduan - CEO & Member of Executive Board
Flavio de Correia - Director of Investor Relations & Corporate Affairs

Conference Call Participants

Luiz Guanais - Banco BTG Pactual S.A., Research Division
Mauricio Cepeda - Morgan Stanley, Research Division
Danniela Eiger - XP Investimentos Corretora de Câmbio, Títulos e Valores Mobiliários S.A., Research Division
Joseph Giordano - JPMorgan Chase & Co, Research Division
Irma Sgarz - Goldman Sachs Group, Inc., Research Division
Tales Granello - J. Safra Corretora de Valores e Cambio Ltda, Research Division
Leandro Bastos - Citigroup Inc., Research Division
Rodrigo Gastim - Itaú Corretora de Valores S.A., Research Division
Lucca Biasi - UBS Investment Bank, Research Division
Gustavo Fratini - BofA Securities, Research Division

Presentation

Operator

Hello, everyone. Thank you for standing by, and welcome to RD Saúde's Fourth Quarter 2025 Earnings Conference Call. This presentation can be found on RD Saúde's Investor Relations website at ri.rdsaude.com.br, where the replay for this conference will also be made available later. [Operator Instructions] Before proceeding, I'd like to mention that forward-looking statements are being made under the safe harbor of the Securities Litigation Reform Act of 1996. Forward-looking statements are based on the beliefs and assumptions of RD Saúde's management and on information currently available to the company.

Forward-looking statements are not guarantees of performance. They involve risks, uncertainties and assumptions as they relate to future events and therefore, depend on circumstances that may or may not occur. Our investors should understand that general economic conditions, industry conditions and other operating factors could also affect the future results of RD Saúde and could cause results to differ materially from those expressed in such forward-looking statements. Today, joining us from the RD Saúde's studio are Mr. Renato Raduan, CEO; and Mr. Flavio Correia, CIO and Corporate Affairs, Chief Officer.

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ultragenyx class action, go to https://rosenlegal.com/submit-form/?case_id=52472 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning Ultragenyx’s expected results for its Phase III Orbit and Cosmic Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta (“OI”). Defendants’ statements included, among other things, confidence in setrusumab’s ability to ultimately trigger a decrease in the OI patients’ annualized fracture rate, alongside confidence in the study designs to demonstrate such ability and reduce testing variability that could interfere with such a result.

The lawsuit claims that defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of setrusumab’s potential, as well as the true risk inherent in the study protocols put forth; notably, that while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates or otherwise, that the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. The lawsuit claims that such statements absent these material facts caused Ultragenyx shareholders to purchase Ultragenyx securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ultragenyx class action, go to https://rosenlegal.com/submit-form/?case_id=52472 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Despite XRP’s continued decline and its struggle to regain the $2 level, one analyst believes the asset is approaching a decisive technical zone that could determine the next rally. A chart breakdown from crypto analyst Egrag Crypto shows that if XRP reclaims key levels above the 200-week EMA, it could strengthen momentum and open the path toward $8.5.

XRP 200 EMA And $1.55 Become Immediate Battleground The projected rally is based on XRP’s interaction with the 200-week EMA, a widely monitored indicator used to assess long-term market momentum. In his accompanying chart, XRP is attempting to move above this moving average while simultaneously approaching a horizontal resistance area around $1.55.

According to him, this zone represents the first meaningful test for bullish strength. A confirmed weekly close above both the 200 EMA and the $1.55 level would indicate that buyers are beginning to regain short-term control of the market. Such a move would signal increasing momentum on the upside and suggest that the recent downward pressure may be weakening.

Source: X Despite this potential shift, the broader technical structure remains intact. The analyst notes that XRP is still trading within a descending channel that has governed its recent price action. As long as the asset remains inside this formation, the larger trend continues to reflect a corrective phase rather than a confirmed breakout.

Because of this, reaching $1.55 signals early strength, but it does not invalidate the broader bearish structure. A sustained trend reversal would only be confirmed after a break above the channel’s upper boundary.

Break Above $2.20 Could Trigger A Rally Toward $8.5 Beyond the initial resistance test, the analyst identifies a higher confirmation level that could trigger a more aggressive bullish phase. The chart points to a weekly close above roughly $2.20 as the next structural milestone for XRP.

A move above this level would place the price beyond key resistance within the descending channel and potentially signal the beginning of a broader expansion phase. In the chart’s projection, such a breakout aligns with higher Fibonacci extension levels, with the longer-term trajectory extending toward the $8.5 region.

However, the chart also outlines a downside scenario if the $1.55 resistance fails to hold. A rejection at that level could trigger a sweep of lower liquidity areas, with the analyst pointing to $1.26 as the first potential downside target.

If weakness persists, the projection shows a deeper move toward the $0.95 to $0.85 region. This area appears on the chart as a broader support zone where price could stabilize before attempting to stage a rally.

For now, XRP’s direction hinges on its interaction with the 200 EMA and the $1.55 resistance level, which the analyst identifies as the key trigger determining whether the market builds short-term strength for a rally or continues its corrective structure.

Price struggles with bears | Source: XRPUSDT on Tradingview.com Featured image created with Dall.E, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter! For updates and exclusive offers enter your email.

I'm Sandra White, a writer at Bitcoinist, and I provide the latest updates on the world of cryptocurrencies. I believe crypto a gateway to a new order and I have made it my life's mission to help educate as much people as possible. When I'm not at work, I love listening to music, learning new things, and dream of traveling around the world.

Bitcoin has experienced a modest recovery after several weeks of persistent selling pressure, allowing the asset to stabilize as broader market sentiment begins to improve. While volatility remains elevated across the crypto market, XRP has recently shown signs of short-term relief, with price action attempting to consolidate after an extended period of downside movement. The shift comes as analysts begin to examine on-chain data for clues about how supply dynamics within exchanges may be evolving.

According to CryptoQuant data, exchange reserve metrics can provide valuable insight into market behavior by tracking how assets move between private wallets and trading platforms. These flows often reveal subtle changes in investor positioning, liquidity conditions, and potential shifts in supply available for trading.

The report highlights the XRP Binance Exchange Daily Flow as a critical indicator. This metric tracks billions of dollars in XRP reserves to reveal how the asset moves across the exchange.

Unlike simple token balance metrics that only count the number of coins stored on the platform, this indicator also incorporates the market price of XRP. As a result, the reserve value reflects two interacting components: the number of XRP tokens held on Binance and the prevailing market price of the asset, providing a more complete view of liquidity dynamics.

Binance Reserve Decline Points To Changing Supply Dynamics The report further explains that exchange reserve data can act as a proxy for available market liquidity. When large amounts of a cryptocurrency remain on trading platforms, those balances represent potential sell-side supply. Conversely, declining reserves often suggest that investors are withdrawing assets from exchanges, reducing the amount immediately available for sale.

XRP Binance Exchanges Daily Flow | Source: CryptoQuant CryptoQuant’s analysis highlights a notable shift in Binance’s XRP reserves. The total dollar value of XRP held on the exchange has fallen sharply, reaching approximately $3.9 billion by March 6. This represents a significant contraction compared with previous peaks observed during the cycle.

Looking back at historical periods provides useful context. The highest levels of XRP reserves on Binance occurred in January and July 2025, when the total value of reserves exceeded $10 billion. During that period, a large quantity of XRP remained on the exchange, indicating abundant liquidity and significant potential selling pressure.

Following those peaks, the market entered a prolonged decline, with XRP eventually dropping more than 60% and trading below $1.35.

From a structural perspective, the current reduction in reserves may alter supply dynamics. When XRP leaves exchanges, the immediately tradable supply decreases. If market demand remains stable while exchange balances shrink, the reduced availability of tokens can gradually ease selling pressure and create conditions that support price stabilization or recovery.

XRP Consolidates After Sharp Correction The chart shows XRP trading near $1.40 following a steep correction that pushed the asset significantly below its previous cycle highs. After peaking above $3.40 during the mid-2025 rally, XRP entered a prolonged downtrend characterized by a sequence of lower highs and sustained selling pressure.

XRP consolidates around a key level | Source: XRPUSDT chart on TradingView Technically, the asset recently broke below its 100-day moving average and remains well under the 50-day and 200-day moving averages, indicating that the broader trend is still tilted to the downside. The sharp drop in early 2026 forced XRP briefly below the $1.20 region before buyers stepped in, triggering a short-term rebound and allowing the price to stabilize in the $1.30–$1.45 range.

This zone is now acting as a temporary consolidation area as the market attempts to absorb the heavy selling pressure that defined the previous weeks. However, the inability to reclaim the $1.50 level highlights that bullish momentum remains limited in the short term.

From a structural perspective, XRP must reclaim the descending moving averages to signal a stronger recovery. The first major resistance sits near the $1.90–$2.00 region, where the 200-day moving average is currently trending.

On the downside, the $1.25–$1.30 zone remains the closest support. Losing that level could reopen the path toward the recent lows near $1.20 if selling pressure intensifies again.

Featured image from ChatGPT, chart from TradingView.com 

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bitcoin Strategist Joe Burnett has shared an ambitious long-term outlook for the BTC price that puts the world’s largest cryptocurrency in the eight-figure range. The projection comes from a research report published on Substack that discusses how major technological and economic shifts could reshape global markets. While the projected price target is bold, Burnett’s reason behind it has drawn significant attention. 

BTC Price Forecasted To Hit $11 Million In 10 Years Burnett has predicted that Bitcoin could climb to roughly $11 million per coin by 2036 if it captures a meaningful share of global financial wealth. The crypto strategist’s ambitious forecast is an updated outlook that builds on a prior thesis he introduced last year, which pointed to a $10 million target by 2035. His new report suggests the structural conditions and reasons supporting that earlier call have not weakened but have actually grown stronger over time.

Burnett’s $11 million Bitcoin price projection assumes that global financial assets will continue to expand over the next decade while BTC gradually strengthens its role as a long-term store of value. In this scenario, Bitcoin’s total market capitalization could reach $230 trillion within a decade. 

With global financial assets expected to approach $2 quadrillion by 2036 if they continue compounding at historical rates, Burnett argues that a $230 trillion valuation would represent only a modest portion of that global wealth. This means Bitcoin would not need to replace existing traditional financial systems to reach such levels. It would simply need to become the most reliable store of value in a world where traditional safe-haven assets are losing their edge. 

Burnett’s thesis also focuses on Bitcoin’s fixed supply of 21 million BTC and its growing appeal among investors seeking protection against currency debasement. As confidence in scarce digital assets grows, he expects more capital to shift toward Bitcoin as a long-term savings vehicle, potentially fueling its price growth.

The AI Deflation Engine Behind The Bitcoin Prediction A key part of Burnett’s argument centers on the economic impact of artificial intelligence (AI). He noted that rapid improvements in AI could increase productivity across industries and significantly lower the cost of producing goods and services. This type of technological prowess can create strong deflationary pressure in the financial economy. 

When prices fall due to efficiency gains, policymakers often respond with monetary expansion to stimulate growth and maintain financial stability. Burnett emphasized that increased liquidity in the financial system could also encourage investors to move toward assets with verifiable scarcity. He noted that Bitcoin stood out in that environment because its supply is permanently capped, making it relatively resistant to the inflation that affects traditional currencies.

The report also points to the potential development of new financial products built around Bitcoin reserves. According to Burnett, lending and credit structures backed by large BTC holdings could bring additional institutional capital into the ecosystem while reinforcing its role as a global reserve asset. 

Burnett believes these structural forces could unfold gradually over the next decade. If they do, the crypto strategist stated that Bitcoin’s rise would be less driven by speculative enthusiasm and “belief” and more by long-term shifts in deflationary pressure, monetary and liquidity expansion, and global capital allocation.

BTC trading at $70,600 on the 1D chart | Source: BTCUSDT on Tradingview.com Featured image from Pngtree, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter! For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts. Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

TL;DR:

More than 31 million ETH have been withdrawn from exchanges, drastically reducing selling pressure. The Coinbase Premium Index has returned to positive territory, signaling a sharp rebound in U.S. institutional demand. Spot Ethereum ETFs recorded net inflows of $169.4 million in a single day. After weeks of stagnation, the trend driving the world’s second-largest cryptocurrency has shifted radically. Ethereum buyers have stepped in with renewed strength, pushing the price up by 2.7% in recent hours to nearly $2,157, in an attempt to shake off months of a bearish trend.

This renewed interest is supported by a massive outflow of over 31 million coins from centralized exchanges. As available reserves on exchanges—especially Binance—decline, a “supply shock” is created, facilitating upward movements as demand begins to accelerate.

Furthermore, for the first time in months, the Coinbase Premium Index has turned green, indicating that U.S. investors are paying a premium for ETH. This indicator is crucial, as it typically precedes phases of institutional accumulation and capital rotation toward the smart contract ecosystem.

Technical Analysis and the Impact of Institutional Flows From a technical perspective, the Relative Strength Index (RSI) has crossed the key level of 50, suggesting that bullish momentum is gaining ground over bearish sentiment. If the price manages to consolidate above immediate resistance, the asset could head toward the 50-day Simple Moving Average (SMA) located at $2,356.

On the other hand, flows into spot ETFs have shown encouraging stabilization after a period of constant outflows. BlackRock’s ETF alone recently captured $39.3 million, reinforcing the thesis that major fund managers are taking advantage of current prices to reposition themselves.

Finally, the growth in Ethereum staking—which now exceeds 31 million locked tokens and one million validators—continues to remove supply from the open market. In summary, the combination of solid on-chain metrics and rising demand positions Ethereum for a potential bullish breakout in the short term.

Exhausted sellers may be giving Bitcoin some breathing room — but analysts say that’s a long way from a recovery.

US Buyers Return, Pushing Prices Off Multi-Week Lows Data from on-chain analytics firm CryptoQuant shows the Coinbase Bitcoin Premium — a measure of US-based buying demand — has flipped from its most negative readings in early February to its highest point since October.

That shift helped carry Bitcoin to a one-month high of $74,000 on Thursday, briefly touching the 50-day exponential moving average. It didn’t last.

By Friday morning, the price had dropped more than $3,000, sliding back below $71,000 as momentum faded almost as fast as it built.

The rally came alongside a wave of ETF inflows and what Nick Ruck, director of LVRG Research, called “renewed risk appetite.” But even as buyers stepped in, the broader conditions hadn’t changed.

Ruck said that the advance “quickly faced headwinds,” with macro uncertainty and softer economic signals pulling the market back down.

Bitcoin is still in a bear market despite the recent rally.

Our Bull Score Index remains at 10/100, deep in bearish territory.

The current move is likely just a relief rally, not the start of a new bull phase. pic.twitter.com/bh4O6jQPD6

— CryptoQuant.com (@cryptoquant_com) March 5, 2026

Bear Market Indicators Remain At Historic Lows CryptoQuant’s Bull Score Index — a composite reading of Bitcoin’s technical and fundamental health — sits at just 10 out of 100. That places it, by the firm’s own assessment, deep in negative territory.

Reports from the firm say the number hasn’t moved despite the recent price action. “Even after the recent price rally, fundamental and technical indicators still point to a bear market environment,” CryptoQuant stated Thursday.

The firm was blunt about what the brief climb likely represents: a short-term release of pressure, not a turning point.

BTCUSD trading at $69,769 on the 24-hour chart: TradingView Unrealized losses among traders and long-term holders had reached levels last seen in July 2022 before the recent easing. That kind of exhaustion can slow a slide without reversing it.

One signal pointing to easing pressure emerged Friday, when analysts said market momentum appears to be approaching a “critical shift.”

According to their assessment, Bitcoin may be moving out of a phase marked by peak negative momentum — a stage that has often preceded broader changes in market direction. What follows that shift, and how quickly it unfolds, remains uncertain.

Macro Headwinds Keep A Lid On Any Optimism February nonfarm payrolls data, expected to show a slowdown, loomed as an added weight on sentiment. Analysts pointed to those “softer macro signals” as a reason cryptocurrencies remain open to fresh downside.

Liquidity conditions had been supportive enough to spark the relief move, but not strong enough to sustain it.

Bitcoin’s brief climb above $74,000 drew attention. The pullback drew more. With the Bull Score Index anchored near the floor and macro conditions still unsettled, analysts are watching for whether US buying demand holds — or fades just like the rally did.

Featured image from Defenders of Wildlife, chart from TradingView

Market Analysis

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Tim Hakki

Web 3 Journalist

Tim Hakki

Part of the Team Since

Feb 2024

About Author

A journalist and copywriter with a decade's experience across music, video games, finance and tech.

Has Also Written

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Last updated: 

2 minutes ago

Global headlines may be dominated by reports of conflict, but crypto is holding steady. According to projections generated by Perplexity, holders of XRP, SOL, and SHIB could still see significant gains this year.

Many say that geopolitical risk may already have been priced into markets after Donald Trump’s previous warnings about possible U.S. military escalation involving Greenland and Iran earlier this year.

With uncertainty still lingering, we examine how realistic Perplexity’s projections are.

XRP ($XRP): Perplexity Projects a Potential 7x Surge by Year-EndIn a recent update, Ripple reaffirmed that XRP ($XRP) plays a central role in the XRP Ledger’s (XRPL) growth into a global payments infrastructure designed for enterprise use.

Source: PerplexityXRP enables near-instant settlement and extremely low transaction fees, positioning the network to capture two rapidly expanding sectors in crypto: stablecoins and tokenized real-world assets.

With XRP currently trading close to $1.36, Perplexity AI predicts the asset could potentially climb to around $10 in 2026, representing a little over sevenfold return for current HODLers.

XRP’s relative strength index (RSI) currently sits near 42, while price movement has begun stabilized around its 30-day moving average, suggesting perhaps the extended consolidation period is nearing its end.

Several catalysts could further strengthen XRP’s outlook, including rising institutional demand following the launch of U.S.-listed XRP exchange-traded funds, Ripple’s expanding network of international partnerships, and comprehensive crypto legislation (the CLARITY Act) in the United States.

Solana (SOL): Could Solana Soon Hit $700?Solana ($SOL) currently secures around $6.7 billion in total value locked and has a market capitalization of $48 billion.

Source: PerplexityInstitutional interest increased after the introduction of Solana-based exchange-traded funds by prominent asset managers such as Bitwise and Grayscale.

However, SOL crashed toward the end of 2025 and spent much of February trading below the $100 mark.

Perplexity sees Solana rising from $84 today to approximately $700 by Christmas. That would give 8x returns and price Solana more than double it’s January 2025 ATH of $293 recorded.

Moreover, major asset managers like Franklin Templeton and BlackRock have begun issuing tokenized assets on Solana.

Shiba Inu (SHIB): Perplexity Forecasts a Potential 2,000% RallyOriginally launched in 2020 as a tongue-in-cheek Dogecoin challenger, Shiba Inu ($SHIB) has since developed into a broader ecosystem with a market capitalization of $3.2 billion.

Source: PerplexityCurrently around $0.000005359, Perplexity’s analysis suggests that a decisive breakout above the $0.000025–$0.00003 resistance range could trigger strong upward momentum. Under that scenario, SHIB could potentially climb toward $0.00008 before the end of the year.

Such a move would represent gains of roughly 15x, or around 1,400%, bringing it a hair’s breadth beneath its October 2021 ATH of $0.00008616.

Beyond its meme coin reputation, the project has introduced practical utility through Shibarium, its Ethereum Layer-2 scaling solution. Shibarium delivers faster transactions, lower fees, enhanced privacy features, and improved developer tools for building decentralized applications.

Maxi Doge: Emerging Meme Coin Aims for Rapid GrowthPerplexity’s projection of a potential 14x surge for Shiba Inu reflects expectations that a new meme coin cycle could accompany the next crypto bull market. However, projects at earlier stages often present even greater growth potential.

One project gaining attention is Maxi Doge ($MAXI), which has already raised $4.7 million through its ongoing presale as early investors accumulate what some believe could become the next Shiba Inu.

Maxi Doge is the loud, louche and degenerate distant cousin to Dogecoin, embracing a comic marketing approach inspired by the chaotic enthusiasm of the 2021 meme coin boom.

MAXI is an ERC-20 asset on Ethereum’s proof-of-stake network, giving it a significantly smaller environmental footprint compared with Dogecoin’s proof-of-work system.

Early participants in the presale can currently stake MAXI for yields reaching up to 67% APY. These rewards gradually decrease as more tokens enter the staking pool.

The token is currently priced at $0.0002807 during the latest presale phase, with automatic price increases scheduled at each new funding milestone. Investors can purchase the token using supported wallets such as MetaMask and Best Wallet.

Stay updated through Maxi Doge’s official X and Telegram pages.

Visit the Official Maxi Doge Website Here